CD276 and neoplasm: Despite the lack of a confirmed receptor, B7-H3 consistently inhibits CD4+ and CD8+ T-cell activation, reducing cytokine production and impairing cytotoxic responses, allowing tumor cells to evade immune destruction (59, 60).